NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · ACHC · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acadia Healthcare Company, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Acadia Healthcare Company, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.46. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acadia Healthcare Company, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics. As of March 31, 2022, the company managed an extensive network consisting of 238 behavioral healthcare facilities, collectively providing approximately 10,600 beds. Established in 2005, Acadia Healthcare is headquartered in Franklin, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | $0.40+14.29% vs estimate | $770.51M+0.09% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.64-14.67% vs estimate | $774.24M-0.61% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | $0.91+1.11% vs estimate | $815.63M+4.6% vs estimate |
|---|
THE ANALYST VIEW
25 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $33.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$176.61+$4.43 (+2.57%)
Universal Health Services, Inc.’s quoted price sits in the lower half of its reported 52-week range, 28.3% below the high.
$13.64+$0.25 (+1.83%)
LifeStance Health Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.11% below the high.
